quantigene

How to Choose the Best Quantigene Services for Fast and Accurate Results

Posted by & filed under Application Notes.

QuantiGene Plex is a powerful tool. The right QuantiGene service can aid drug discovery and development. It can be a great addition to your lab’s tools for clinical research. 

Notice we said the “right” QuantiGene service. How can you tell the difference between the best QuantiGene services and the ones you should avoid? 

That’s exactly the question we will answer in this guide. 

Read on to peruse our checklist for picking the right QuantiGene Plex service. 

QuantiGene Qualifications to Seek

We’re not going to play favorites when it comes to mentioning specific services. Instead, we’ll show you what to look for in a QuantiGene service. Once you know what to look for, you can make an informed decision for yourself.

Take a look, and begin your education. You’ll be a QuantiGene expert in no time.

Quantity of RNA Targets

The point of QuantiGene is quantity. The word factors into the name of the service itself. Thus, you want to guarantee you’re finding a QuantiGene service that can measure as many genes as possible.

A good QuantiGene service should have the equipment to measure up to 80 genes.

No RNA Purification Required

RNA purification has its uses. Involvement in branched DNA assay does not have to be one of them.

We see RNA purification as an extra, unnecessary step in the assay. Many QuantiGene Plex companies see it the same way. That’s why they offer their services without the need for RNA purification.

When a service does not require RNA purification, it can work with degraded tissues and directly with blood. All of these things simplify the workflow, making your research easier and clearer. 

Check the Inventory

You’re going to use your QuantiGene Plex assay to create pathway-themed and disease-themed panels. These are complex panels that require analysis of multiple genes. You can’t run a disease panel when you only have a few genes to validate against.

You choose should choose a service that has an in-depth inventory of validated genes. This will give you the most thorough assay. 

It’s reasonable to expect your QuantiGene Plex service have an inventory of thousands of validated genes, and not low thousands. We’re saying around 15,000 genes is the ballpark you want to be in. 

Customization

Finding a service that can create custom panels quickly is just good sense. You want a QuantiGene service that can be a true partner to your lab. If you need a custom panel, your QuantiGene service should oblige. 

Custom panels are always going to take longer than standard panels to create. You should expect a little extra wait time. We think within a couple weeks is a reasonable standard. 

Plex Your Lab’s Muscles

Forgive the terrible pun, but it points to a truth. If you choose a high-quality QuantiGene Plex service, your research will grow stronger. We hope this guide has given you insight into how to find that service.

A lot of your search should be about quantity. Can they measure a lot of targets, and do they have a large inventory? If the answers to those questions are both “yes” and they can do their work quickly, you’ve got a winner on your hands.

Check out our services for more in-depth help with QuantiGene technology. 

The Anti-SM Antibody: An Overview for Medical Professionals

Posted by & filed under Programs & Events.

The human body functions in amazing ways to keep foreign invaders from entering. Upon detection, immune cells act to neutralize and remove pathogens.

They tag them as dangerous, endocytosis, phagocytosis, and pinocytosis. Blood proteins called antibodies essentially sniff out specific antigens, discerning between self and non-self particles. Then, they appropriately dispose of them.

Unfortunately, the body gets mixed up sometimes and begins to produce antibodies that don’t make this crucial discernment correctly. As a result, they attack healthy cells. We see this in autoimmune diseases, such as systemic lupus erythematosus (SLE).

SLE is a chronic inflammatory autoimmune disease characterized by inflammation that affects the skin, muscles, bones, heart, lungs, and peripheral nervous system. With this disease, keratinocyte, and monocyte apoptosis increases along with the Fas ligand expression in T and B cells and T cell necrosis.

Antibody research revealed that one of the most important nuclear antibodies for diagnosing autoimmune diseases in clinical practice is the anti-Sm antibody. Let’s look at the specifics on the anti-Smith antibody and its clinical importance regarding SLE.

The Anti-Sm Antibody

This antibody targets the following proteins that compose U1, U2, U4, and U5 small nuclear ribonucleoprotein particles:

  • B/B’
  • D1
  • D2
  • D3
  • E
  • F
  • G

In some individuals suffering from lupus, dead cells release the anti-smith antibody. It combines with anti-RNP antibodies to form a self-reactive B cell protein complex.

Why Is It Clinically Important in Diagnosing SLE?

The anti-Smith antibody is present in about 20-30% of patients. Most of these patients are Asian and African American.

A higher percentage of patients with SLE present with anti-RNP antibodies. However, doctors find that the anti-Smith antibody test more accurately diagnoses the disease because this antibody doesn’t tend to present in other rheumatological afflictions, whereas anti-RNP does.

When Is It Appropriate to Test for Anti-Smith Antibody?

The doctor should test for this antibody if they suspect that the patient may suffer from SLE. Signs and symptoms that may help you decide to test include:

  • Headaches
  • Swelling and pain in the joints
  • Serositis
  • Severe fatigue
  • Anemia
  • A butterfly rash
  • Unexplained hair loss
  • Raynaud’s phenomenon

You can also use this antibody test to help diagnose mixed connective tissue disease. Test results will read as positive, equivocal, or negative and will typically come through in about 5-7 days.

A doctor may run this antibody testing instead of or in conjunction with the Antinuclear Antibody test, the Antiphospholipid Antibodies test, the Anti-dsDNA test, the C-Reactive Protein test (CRP), and a complement test.

Can We Counteract the Anti-Sm Antibody?

A C-type lectin with two identical halves, called CD72, provides hope for effectively battling SLE without causing significant damage to other cells. Research shows that the regulatory protein CD72 actually inhibits the complex formed by anti-sm and RNP antibodies by binding to it.

Trust Only the Best for Important Medical Tests

If your patient presents with signs and symptoms of SLE, put together your panel of lab tests with only the most trusted products and equipment available.

Remember the clinical importance of the anti-Sm antibody when putting together the panel. Contact us for all of your biomedical research kits, genomics, and proteomics and mass spectrometry services.

An Overview of Protein Assay Methods

Posted by & filed under Programs & Events.

Proteins are one of four macromolecule building blocks that are necessary for any form of life. That’s why being able to analyze proteins with a protein assay is crucial in both research and diagnosis.

Total protein assay kits can be used to determine the total protein concentration of a sample.

To help you choose the right method to measure your protein, read this review of the main protein quantification methods.

Bicinchoninic Acid (BCA) Assay

This colorimetric, two-step protein concentration assay was first developed in 1985. It is relatively young compared to others, such as the Lowry assay.

First, complex the protein by using copper ions. Next, the copper that is now bound with the protein will give off a vibrant purple hue. The shade of purple corresponds to the amount of protein in the sample.

Then, compare the sample to the standard curve to determine the protein.

The BCA assay is a good choice if your protein sample has less than 5% detergents. As this method relies on copper, certain chemicals can interfere with the BCA assay, such as ammonia.

Bradford (Coomassie) Assay

Bradford Assays bind the protein to Coomassie dye in acidic conditions. As a result, the color changes from brown to blue.

When the Coomassie dye binds to the amino acids in the protein, it becomes blue and absorbs at 595 nm. The absorption in your sample can then be compared to a standard curve to determine the protein concentration.

This method is simple, fast, and stable for around 60 minutes. Keep in mind that it only works on proteins larger than 3 kDa. Unlike the BCA, the Bradford is sensitive to certain detergents, such as SDS and Triton X-100.

Folin-Lowry

The Folin-Lowry is a reliable and time-tested protein quantification that dates back to 1951. This has two steps.

Step one: complex copper with nitrogen found in your protein. Step two: the now complex tyrosine and tryptophan will react with the Folin-Ciocalteu phenol reagent to give off a greenish blue shade that absorbs at 650-750 nm.

The great thing about this assay is that the results are stable. So you can estimate how much protein is in your sample by comparing it with a previous standard curve.

The downside of this assay is that it is incompatible with many chemicals and reducing agents.

HPLC (High-Performance Liquid Chromatography)

In a liquid chromatography protein concentration assay, the sample is transported through an absorbent column by a solvent at high pressure.

Each amino acid side chains will react differently. The ones that react least will move down the column more quickly than the side chains that react the most.

As fractionated proteins flow out of the column, each fraction is identified either by UV spectrometry or by mass spectrometry. A dye can be used to make detection easier.

Final Thoughts on Protein Assay

Thanks for reading. We hope you found this list of the various commonly used protein assay quantification methods useful.

Next, check out ProDM, a kit for tryptic digestion monitoring for a successful shotgun proteomics.

ITSIBIO awarded SBA REGION 3 Exporter of the year.

Posted by & filed under Press Coverage & Press Release.


… 68 district winners, his nomination was forwarded to their respective regional office – in this case Region 3, which spans Delaware, Philadelphia, Pittsburgh, Maryland, Virginia, Washington, D.C., and West Virginia – where he became the regional winner. The breast cancer screening effort is funded by a grant from the National Institute of Health …

Read full article

ITSIBIO NEWFLASH Issue 2

Posted by & filed under Programs & Events.

iTRAQ detects eEF1A1 as a candidate biomarker for Metastatic Progression of Prostate Cancer

ITSI-Biosciences’ latest newsflash publication, “iTRAQ detects eEF1A1 as a candidate biomarker for Metastatic Progression of Prostate Cancer” discusses how PSA is plagued with controversies and is unreliable because of its potential to provide false positive and false negative results. Hence additional biomarkers are needed to replace or compliment PSA to improve detection, diagnosis and prognostication of prostate cancer.

Download full newsflash article

ITSI BIOSCIENCE RENEWED ITS BLANKET PURCHASE AGREEMENT WITH NIH

Posted by & filed under Programs & Events.

ITSI-Biosciences has renewed its Blanket Purchase Agreement (BPA#: HHSN263200900168B) with the NIH

Our products and services are customized for researchers interested in biomarker discovery/validation and protein expression monitoring using human and non-human models. We strive to deliver the best products and quality results to you on a timely basis and within your budget.

We would like to invite you to take advantage of the BPA and have a personal experience with our quality products and customer-focused service. If you order any of our services or products before September 31, 2011, you will receive a 15% special discount (quote “NIH09/31/11”). Please visit our website at: www.itsibio.com or contact us at: itsi@itsibio.com for more information.

MARCH 05, 2012 ITSI BIOSCIENCES PRESENTS MOST OUTSTANDING DISTRIBUTOR OF THE YEAR & BEST NEW DISTRIBUTOR OF THE YEAR.

Posted by & filed under Press Coverage & Press Release.

ITSI-Biosciences is pleased to announce that Concurrent Technologies and Services (CTS) and Biomax Co, LTD have been selected as the 2011 “Most Outstanding Distributor of the Year” and “Best New Distributor of the Year”, respectively.

ITSI-Biosciences distributors’ award recognizes re-sellers of our products for their sales and marketing excellence and for working with ITSI-Biosciences to satisfy the needs of clients.  Under the most outstanding distributor category, distributors were evaluated based on the following:

  1. Percent increase in sales from the previous year.
  2. Total value of products ordered.
  3. Variety of products ordered.
  4. Timely communication of market intelligence and customer feedback to ITSI-Biosciences.

 

To win the award, a distributor must place first in at least three of the four categories. Concurrent Technologies Nigeria Limited achieved the highest score for total annual product sales, percentage increase in sales for the past 12 months and the variety of products ordered. Funakoshi of Japan, the winner in 2010 and 2011 placed second overall.

Biomax Co Ltd of South Korea won the “Best New Distributor” award.  This award is given to a new distributor who has demonstrated a high level of commitment towards the promotion and selling of our products in their territory. To win the award in the year they were appointed, a distributor must place first in at least two of the following three categories; a) Total value of the products ordered, b) Variety of products ordered and c) Timely communication of market intelligence and customer feedback to ITSI-Biosciences.

In appreciation of their efforts, CTS and Biomax will receive our authentic 2012 Distributor of the Year Award, a certificate and an additional 15% off on all confirmed orders for ITSIPrep Bioanalytical Kits and ITSIPrep Accessories placed with ITSI Biosciences during the month of April 2012.
ITSI-Biosciences congratulates Concurrent Technologies Services and Biomax Co. LTD for this well-deserved award and look forward to continue working with them to increase our market share.

JUNE 22, 2010 Unique New Product Line Launched by ITSI BIOSCIENCES

Posted by & filed under Press Coverage & Press Release.

Johnstown, PA ITSI Biosciences is pleased to announce the introduction of a unique line of space-saving laboratory instruments ideal for laboratory and field use. This new line includes the ITSI Vortex Mixer and the ITSI Magnetic Stirrer for use in laboratories and field research.

Both units operate with a small electrical (6V) adapter or batteries (4×1.5v). Each weighing only 200g, they are small, light weight and portable. The ITSI Vortex Mixer and Magnetic Stirrer allow for easy movement around the laboratory with no cable clutter. “You will hardly know they are on the bench until you need to use one. Being battery operated and compact makes these units ideal for field use and for laboratories with limited bench space” says Dr. Richard I. Somiari, President and Chief Scientific Officer.

Dr. Somiari states “We are pleased to announce this addition of portable and space-saving instruments which complements our sample preparation kits and other scientific product line. Both units are cost effective, practical additions for any scientist working in industrial, agricultural, medical, environmental, government or academic research.”

The Vortex Mixer and Magnetic Stirrer can be purchased online at www.itsibio.com or by calling ITSI Biosciences (814)262-7331.

MAY 20, 2010

Posted by & filed under Press Coverage & Press Release.

ITSI-Biosciences (www.itsibio.com) today announced that Cheryl Napier, M.S is the lucky winner of the Acer Net Book that was displayed at ITSI- Biosciences booth during the 2010 American Association for Cancer Research Annual Meeting in Washington D.C from April 17 – 21. Mr. James White, Economic Development Coordinator for the City of Johnstown, PA drew the lucky entry from over 100 entries.

JANUARY 19, 2010 ITSI BIOSCIENCES PRESENTS DISTRIBUTOR OF THE YEAR AWARD

Posted by & filed under Press Coverage & Press Release.

Johnstown, Pennsylvania, USA ITSI Bioscience a leading global proteomics, genomics and bioreagent solutions company located in Johnstown, PA has awarded Funakoshi Co., Ltd of Tokyo, Japan their prestigious Distributor of the Year Award for 2009.

Criteria for the award included new sales volume, market penetration and customer satisfaction. This year’s award winner, Funakoshi Co., Ltd has contributed to the growth of Johnstown based Integrated Technologies and Services International (ITSI Biosciences) as an important life science company supplying innovative products to the scientific communities in Japan.To win the award, Funakoshi placed at the top of all three criteria ahead of distribution partners located throughout Africa, Asia, North America, South America and the Middle East.

Dr. Richard Somiari, PhD, President & CEO, indicates “The Distributor of the year award is a way for us to say thank you to a company who has worked with ITSI as an invaluable team member and contributing to our overall success.” “We are honored to work with an organization like the Funakoshi Company to achieve our corporate goals. The international market place is a very competitive environment and successful partnerships abroad are essential to our continued international growth trend.”

“I don’t know if we are worthy of such a great honor, but we are grateful. It will encourage us to make more efforts to expand the market share of ITSI Biosciences in Japan,”  says Shinya Ichikawa, Marketing Specialist, International Business Department at Funakoshi Company.

In appreciation of their efforts, Funakoshi Co. will receive a 2009 Distributor of the Year award, certificate and an additional 10% off all orders placed with ITSI Biosciences during the month of February 2010.

DECEMBER 04, 2009

Posted by & filed under Press Coverage & Press Release.

ITSI Biosciences is pleased to announce the addition of Richard Cosgrove as Vice President of Operations and Business Development to the organization.

Mr. Cosgrove will be directly responsible for all aspects of business development and marketing to help ITSI Biosciences expand its domestic and international market share in academic, corporate and government sectors, as well as managing operations of the company™ business units.

According to Richard Somiari, PhD, President and CEO, “We are extremely pleased to have Rick join us at this important time in the growth of the company. Our future in the national and international market place is very bright, and Mr. Cosgrove will focus on consolidating existing markets and working to open up new business opportunities in government, the defense industry and pharmaceutical companies”.

Mr. Cosgrove comes with extensive marketing and management experience in the healthcare industry. He holds a Master’s degree in Liberal Arts/International Studies from Lock Haven University, Advanced Graduate Studies International Business Management certificate from Point Park University and a Bachelor of Science degree, in Marketing from Indiana University of Pennsylvania. Rick has previously held positions at HealthSouth Corporation and University of Pittsburgh Medical Centers and is Adjunct Professor of Marketing/Management at the University of Pittsburgh at Johnstown. He is a member of the Board of Directors of the Greater Johnstown/Cambria County Chamber of Commerce, where he is the chairman, Government Action Committee. Mr. Cosgrove is a member of the I.U.P.  Eberly College of Business and Technology’s business advisory board, Johnstown Symphony Orchestra’s board of advisors and is chairman of the American Heart Association Cambria/Somerset Heart Ball 2010.

ITSIBIO NEWFLASH Issue 1

Posted by & filed under Programs & Events.

Proteomics on Formalin-Fixed Parafin-Embedded Tissues

ITSI-Biosciences’ latest newsflash publication, “Proteomics on Formalin-Fixed Parafin-Embedded Tissues” discusses how Formalin-Fixed Paraffin Embedded Tissues (FFPE) are commonly used in healthcare to preserve tissues from a wide variety and different stages of a disease. However formalin cross links the protein and poses a great obstacle for downstream proteomics application.

Download full newsflash article

APPLICATION NOTE: ITSIPREP KITS FOR 2D-DIGE

Posted by & filed under Programs & Events.

ITSI-Biosciences’ latest application note, “ITSIPrep Kits for Two Dimensional Difference in Gel Electrophoresis” discusses how to:
1) Achieve great results in 2D-DIGE experiments.
2) Streamline and standardize the up-stream sample preparation steps including protein isolation, fractionation, precipitation and depletion.
3) Avoid the use of poor quality reagents and inadequate protocols which results to poor quality data and waste of time and money.

Download full application note

May 05, 2011 ITSI BIOSCIENCE AWARDED SMALL BUSINESS EXPORTER OF THE YEAR

Posted by & filed under News.

ITSI-Biosciences wins Small Business Exporter of the Year, and is being awarded by The Saint Francis University Small Business Center, Friday June 17th, 2011. This award recognizes the outstanding achievements of the Southern Alleghenies Region’s most successful entrepreneurs and small business advocates.

March 04, 2011 ITSI BIOSCIENCE FEATURED IN COMMERCIAL NEWS USA MAGAZINE: AMERICAN EXPORTERS

Posted by & filed under News.

ITSI-Biosciences featured in Commercial News USA, the official export magazine of the U.S. Department of Commerce.
Commercial News USA is the premiere export promotion program for promoting U.S. goods and services in more than 178 countries around the world. The catalog-style magazine reaches more than a quarter million buyers and distributors worldwide. The magazine is direct-mailed to subscribers around the world, and also is distributed at U.S. embassies and consulates, as well as at major trade shows.

In addition to us being included in the print edition, we receive a free listing, email and Web links in both the pdf and html versions of the magazine on their Web site.

Click here to view advert

February 17, 2011 FUNAKOSHI WINS 2010 DISTRIBUTOR OF THE YEAR AWARD

Posted by & filed under News.

Funakoshi Co., Ltd of Tokyo a leading distributor of bioreagents in Japan has been named the ITSI-Biosciences 2010 “Distributor of the Year”. This is the second time that Funakoshi is wining this distinguished and highly competitive award. Funakoshi Co., Ltd has continued to contribute to the growth of ITSI-Biosciences products in Japan.

Criteria for selecting the award winner included a) overall number of items ordered in 2010, b) frequency of order, c) the different types of products ordered d) communication of feedback from customers to ITSI-Biosciences. To win the award, a distributor must place first in at least three of the four categories. Funakoshi placed first in three categories and second in one category, outperforming other international distributors.

According to Dr Richard I. Somiari, President/CSO, “this unique partnership leverages Funakoshi and ITSI-Biosciences strengths to bring innovative life science products to scientists in Japan at a competitive price”.

“It is a great honor to receive this award. We really hope that ITSI-BIOSCIENCES will dramatically boost their market forces in 2011. Of course, we will also exert our utmost efforts to establish their market in our sales territory as before.” says Shinya Ichikawa, Marketing Specialist, and International Business Department at Funakoshi Company.

In appreciation of their efforts, Funakoshi Co. will receive an authentic 2010 Distributor of the Year award, a certificate and an additional 10% off on all orders placed with ITSI Biosciences during the month of March 2011.

Click here to view Award

December 7, 2010 Christopher P. Koop, from Congressman Mark Critz office visited ITSI-Biosciences

Posted by & filed under News.

Mr. Koop toured the new state-of-the-art facility to learn more about ITSI’s business and operations in Johnstown. As Congressman Critz’s field representative Mr. Koop is helping ITSI-Biosciences establish strategic relationships, expand operations and take advantage of the unique opportunities for life science and biotechnology companies in the Johnstown area and 12th congressional district.

June 30, 2010 Visiting PhD Research Fellows commence Breast Cancer and Sickle Cell Research at ITSI-Biosciences

Posted by & filed under News.

Two PhD Research Fellows from Olabisi Onabanjo University, Nigeria, arrived in Johnstown, PA today to commence research programing at ITSI – Biosciences. The two students will be in the United States for 6 months researching on Sickle Cells and Breast Cancer.

Picture Legend from the left: Mutu A. Alabi (Phd Research Fellow in Breast Cancer), Teresa Dugan (Consultant/Training Specialist) and Olaleken H. Oyefuga (Phd,Research Fellow in Sickle Cell)

July 28, 2010 President and Chief Executive Officer of Protein Discovery visits ITSI-biosciences

Posted by & filed under News.

Chuck Witkowski founder of Protein Discovery visits ITSI-Biosciences facility today. Mr Witkowski is is a visionary leader with demonstrated expertise in building successful medical and life science companies from inception.

Picture Legend from the left: Dr. Richard Somiari (President & Chief Scientific Officer of ITSI-Biosciences), Chuck Witkowski (President & Chief Scientific Officer)

June 21, 2010 ITSI-Biosciences host summer interns

Posted by & filed under News.

“ITSI – Biosciences host summer interns”. Five students will be at ITSI – Biosciences for 7 weeks as interns. Three are high school graduates; Nicole Danchanko that will be going to Penn Highlands Community College in the fall to study Biology, Richard Somiari Jr going to Lehigh University also in the fall to study Computer Engineering and Jamie Lepsch going to Robert Morris University to also study Computer Engineering. Two are college students; Zach Evans a sophomore from the George Washington University majoring in International Affairs, Jasmine LaRue majoring in Biology at Mount Aloysius College.

March 01, 2010 DHQ KMS personnel commence training in San Antonio

Posted by & filed under News.

ITSI, LLC today announced the commencement of the second phase of the training for the visiting Nigerian Defence Headquarters (DHQ) Knowledge Management System (KMS) project personnel in San Antonio, TX.

This phase of the training is provided by BIF Technologies of San Antonio, TX. BIF is ITSI’s technical partner for implementation and management of the DHQ-KMS program.

March 1, 2010 Nigerian Armed Forces DNA Bank and Analysis personnel visit Cybergenetics Corporation, Pittsburgh, PA.

Posted by & filed under News.

ITSIBIO today announced that ITSI Biosciences and Cybergenetics (www.cybgen.com) are collaborating to train the Nigerian Armed Forces DNA Bank (AFDB) personnel, and implement modern methods for forensic DNA analysis and interpretation in Nigeria. As part of this strategic relationship 6 AFDB personnel undergoing training at ITSI Biosciences since September 2009 have visited and trained at the CyberGenetics facility in Pittsburgh, PA from December 16th 17th, 2009. Cybergenetics is a leader in producing unique computational approaches for automating and simplifying forensic DNA data processing, analysis and interpretation. The Cybergenetics TrueAllele® system enables rapid and automated forensic DNA data analysis and interpretation.

February 17, 2010 2B Scientific, United Kingdom appointed distributor for Europe.

Posted by & filed under News.

ITSIBIO has signed a representation and distribution agreement with 2B Scientific Limited, Upper Heyford, United Kingdom. 2B Scientific (www.2bscientific.com), a specialist reagents distribution company to the UK Life Science Markets will serve as a springboard for European markets. This appointment gives 2B Scientific the rights to promote, market, distribute and sell ITSIBIO products in Europe. Clients in this territory can now place orders for all ITSIBIO products through 2B Scientific.

February 4, 2010 Nigerian Defense Headquarters, ITSI – Biosciences representative visit Nigerian Armed Forces DNA Bank (AFDB) in Abuja, Nigeria.

Posted by & filed under News.

ITSIBIO today announced that Nigerian Defence Headquarters Research and Development leaders, Major Gen BT Obasa (Chief, Research & Development) and Air Vice Marshall A Badeh (Director of Research) and Dr Richard I. Somiari (President & CSO) ITSI – Biosciences, LLC toured the Nigerian Armed Forces DNA Bank at Mogadishu Barracks, in Abuja, Nigeria. ITSI Biosciences is helping the Nigerian DHQ develop a Genvault technology based DNA bank capable of banking DNA from 100,000 military personnel. A total of 6 AFDB personnel are currently undergoing DNA banking and analysis training at ITSI Biosciences, Johnstown PA. As part of the training, the AFDB personnel have also spent time at Indiana University of Pennsylvania, Indiana, PA, Cybergenetics, Pittsburgh, US Armed Forces DNA Identification Laboratory (AFDIL), Rockville, MD. The visit was to assess the readiness of the facility to receive the trainees who will return to Nigeria in April 2010.

Picture Legend: Nigerian DHQ Research & Development leaders and ITSI representative visit the Armed Forces DNA bank in Abuja, Nigeria. From right: Maj Gen BT Obasa (Chief Research & Development, DHQ), Richard I. Somiari, PhD (President & CSO, ITSI Biosciences) and AVM Badeh (Director of Research, DHQ)

January 20, 2010 Nigerian Armed Forces DNA Bank (AFDB) personnel visit US Department of Defense AFDIL and AFRSSIR.

Posted by & filed under News.

ITSIBIO today announced that 6 Nigerian AFDB personnel visited the United States Department of Defense (DoD) Armed Forces DNA Identification Laboratory (AFDIL; www.afip.org/consultation/AFMES/AFDIL/index.html) in Rockville, MD and Armed Forces Repository of Specimen Samples for the Identification of Remains (AFRSSIR; www.afip.org/consultation/AFMES/AFDIL/AFRSSIR/) in Gaithersburg, MD. The visit is part of the comprehensive forensics DNA banking and analysis training organized by ITSI Biosciences, Johnstown, PA for the Nigerian Armed Forces DNA Bank and Analysis personnel. The visit allowed the AFDB personnel to tour both facilities and observe first-hand how DNA is collected, stored at room-temperature and analyzed by the US military in support of military missions.

December 9, 2009 US Armed Forces DNA Identification Laboratory (AFDIL) Education team arrive Johnstown, PA to train Nigerian Armed Forces DNA Bank personnel.

Posted by & filed under News.

ITSIBIO today announced that instructors from AFDIL based in Rockville, MD have arrived Johnstown, PA to help train Nigerian Armed Forces DNA Bank (AFDB) personnel. The AFDIL team led by Michael D. Coble, PhD (Research Section Chief) arrived in Johnstown, PA on the 8th of December 2009. According to Richard Somiari, PhD, President of ITSI, LLC “the training will focus on military applications and cover; 1) Forensic DNA Analysis 2) Short Tandem Repeat (STR) Data Analysis and Interpretation 3) Population Genetics and Statistics and 4) Non-STR DNA Markers. ITSI LLC (www.itsi.us; www.itsibio.com) is helping AFDB setup a state-of-the-art DNA banking and analysis center in Abuja, Nigeria that will be capable of banking DNA from up to 100,000 military personnel. The involvement of AFDIL in the training program is critically important and key to achieving the overall project goals added Dr Somiari.

December 7, 2009 Nigerian Defence Headquarters personnel commence computer science and Knowledge Management System training in Johnstown, PA.

Posted by & filed under News.

ITSI, LLC today announced the arrival of 6 Nigerian Defence Headquarters (DHQ) personnel in Johnstown, PA to commence five months computer science and knowledge management system training. According to Richard I Somiari, President and CEO of ITSI, the training is part of the MOU between DHQ and ITSI concerned with the design, construction and setting up of a prototype knowledge management system for DHQ. Several organizations including Pennsylvania Highlands College, Johnstown PA; BIF Technologies, San Antonio, TX and ThreatGuard, San Antonio, TX have teamed up with ITSI, LLC to provide the training.

December 04, 2009 ITSI Biosciences is plea sed to announce the addition of Richard Cosgrove as Vice President of Operations and Business Development to the organization.

Posted by & filed under News.

Mr. Cosgrove will be directly responsible for all aspects of business development and marketing to help ITSI Biosciences expand its domestic and international market share in academic, corporate and government sectors, as well as managing operations of the company’s business units. According to Richard Somiari, PhD, President and CEO, “We are extremely pleased to have Rick join us at this important time in the growth of the company. Our future in the national and international market place is very bright, and Mr. Cosgrove will focus on consolidating existing markets and working to open up new business opportunities in government, the defense industry and pharmaceutical companies”.

Mr. Cosgrove comes with extensive marketing and management experience in the healthcare industry. He holds a Master’s degree in Liberal Arts/International Studies from Lock Haven University, Advanced Graduate Studies International Business Management certificate from Point Park University and a Bachelor of Science degree, in Marketing from Indiana University of Pennsylvania. Rick has previously held positions at HealthSouth Corporation and University of Pittsburgh Medical Centers and is Adjunct Professor of Marketing/Management at the University of Pittsburgh at Johnstown. He is a member of the Board of Directors of the Greater Johnstown/Cambria County Chamber of Commerce, where he is the chairman, Government Action Committee. Mr. Cosgrove is a member of the I.U.P.  Eberly College of Business and Technology’s business advisory board, Johnstown Symphony Orchestra’s board of advisors and is chairman of the American Heart Association Cambria/Somerset Heart Ball 2010.

September 02, 2009 Armed Forces DNA Bank (AFDB) personnel commence DNA banking and analysis training at ITSI-Biosciences

Posted by & filed under News.

Six members of the Nigerian Armed Forces DNA Bank (AFDB) representing the Army, Navy and Air force, arrived in Johnstown, PA today to commence DNA banking and analysis training at ITSI Biosciences. The team will be in the United States for 8 months learning new DNA banking and analysis methods. According to Richard Somiari, PhD, President of ITSI Biosciences, the training is part of the strategic relationship between ITSI Biosciences and the Nigerian Defense Headquarters concerned with the establishment of a state-of-the art DNA bank and analysis center for the Nigerian military. When fully implemented, the Nigerian Defence Headquarters DNA banking initiative which is the first military large-scale DNA banking initiative of its kind in Africa will have capacity to bank DNA from up to 100,000 military personnel.

AFDB Personnel: Abiodun Ebenezer Adebiyi(Lt. Col, Army), Chidi Innocent Onuoha(L/Cpl, Army), Olarewaju Anthony Ogundele(PO Navy), Anthony Friday Akpan(FS, Air Force), Ikwoegbu Mba Igbe(Sqn. Ldr, Air Force), Livinus Ukachukwu(Lt. Cdr. Navy).

February 1, 2009 ITSI Biosciences moves into new larger facility with ISO Certified Clean Room

Posted by & filed under News.

ITSIBIO today announced its movement into its new and larger facility. The new state-of-the-art facility in the Kernville district of Johnstown, PA is a green building with a silver status. The new facility includes more office space, expanded research laboratory and kit manufacturing space, and an ISO Certified Class 1000 clean room. This move is another step in our company’s growth strategy states Richard Somiari, PhD, founder and president of ITSI Biosciences. ITSIBio continues to be successful in delivering innovative services, developing easy-to-use sample preparation kits and securing competitive grants for cancer biomarker development.

January 19, 2009 ITSI Biosciences launches packaging for ITSIPrep products

Posted by & filed under News.

ITSIBIO today announced the introduction of a new and improved packaging for its distinctive line of ITSIPrep products. The new colorful and distinctive packaging is a marketing tool that reflects the key attributes of ITSIPrep line of products. This new packaging replaces the plain white package that the company has been using for three years. According to Richard Somiari, PhD, President of ITSI Biosciences this new package will distinguish ITSI Biosciences products, and provide better protection to the contents during shipment of our innovative products to customers in the USA and around the world.

January 5, 2009 ITSI Biosciences is a subrecipient of a 5 year $2 million RO1 grant to study prostate cancer

Posted by & filed under News.

ITSI Bioscience has announced that it is a Subrecipient of a $2 million 5 year RO1 grant awarded to Dr Karam El-Bayoumy of Penn State University Cancer Center. This NCI subaward will fund proteomics research at ITSI Biosciences, focusing on the identification of biomarkers of prostate cancer risk. Specifically, ITSIBio will utilize high performance 2D-DIGE MS and nano-LC/MS/MS to identify and characterize redox-sensitive proteins, and global proteomic patterns associated with the form and dose of selenium administered to human subjects, and those associated with the age of the subjects.

December, 2008 New lab, NCI funding provide ITSI-Biosciences with broader base for new breast-cancer detection test

Posted by & filed under News.

Dr. Richard Somiari, the founder of ITSI Biosciences, a life-science enterprise in the Johnstown region, is preparing to move his company into its new headquarters by year’s end–just in time to expand field investigations of a blood-sampling method that promises to increase the speed and lower the cost for early detection of breast cancer. That work received a $100,000 Small Business Innovation Phase I Research Grant from the National Cancer Institute in July.

After what appears to be a long search for the right space, ITSI-Bio’s third move promises to be a charm for a four-year-old business that represents a bellwether for the efforts to attract a cluster of life-science enterprises to the Johnstown region.

“We’ve been carrying on our work in about 1,500 square feet and need the flexibility of a custom-built laboratory,” Somiari says from his present location in the Kernville neighborhood of Johnstown, Cambria County. The new location will place the company, which provides analytical services and sampling kits for bioscience laboratories worldwide, in a 10,000-square-foot facility nearer the heart of Johnstown.

ITSI-Bio will initially occupy half of that area, where it will be able to broaden its basic analytical services to bioscience researchers. In addition to analytics, the company also offers kits for isolating, handling, testing, and monitoring proteins, as well as reagents used to tag biochemical reactions. “That business has kept the doors open while we have pursued our method for early breast cancer detection,” Somiari says.

The detection protocol draws upon about 20 biological markers, some of which have been clearly associated with breast cancer and others that Somiari has identified for the blood-sample analysis that he hopes to demonstrate as a faster and more precise testing method.

While that goal has directed his passion as a scientist, he has been closely identified with the future of biotech in Johnstown. He came to the region from the University of Maryland in 2000 to start the Windber Research Institute, the region’s first biomedical research institute. Only later did he form his own company to develop a commercial product–deciding, as he says, that it would be a good idea to practice the entrepreneurship that he had been preaching.

The NCI grant will finance expansion of the breast-cancer-test sampling and independent validations of results through UPMC McGee Hospital, Indiana Regional Medical Center, and the Department of Biomedical Informatics at the University of Pittsburgh. It will also support the development of algorithms to analyze results, as well as development of a Phase II NCI grant for up to $1 million.

Source: ITSI-Biosciences, Richard I. Somiari
Writer: Joseph Plummer
Original Article: http://www.keystoneedge.com/innovationnews/itsibio1204.aspx

November, 2008 ITSI Biosciences receives $100,000 Phase 1 SBIR Grant from NCI for breast cancer research

Posted by & filed under Programs & Events.

ITSI – Bioscience www.itsibio.com has announced the receipt of a $100,000 Small Business Innovation Research (SBIR) Phase 1 grant from the National Cancer Institute. The grant will support ITSIBIO’s ongoing blood-based breast cancer detection biomarker program that promises to provide an alternate method for earlier detection and accurate classification of breast malignancies.

At the moment mammography is the most widely used screening tool for breast disease detection and diagnosis. Unfortunately, mammography can miss some breast cancers, especially in young women with dense breast, it cannot unequivocally distinguish between benign and malignant lesions and it can not be performed remotely. If successfully validated, the proposed blood test would be beneficial to all women who show abnormalities in their mammograms and require further testing. Most of these women currently endure biopsies, up to 80% of which are probably unnecessary, as no cancer is found.

According to Richard Somiari, PhD principal investigator for the study titled “development of a blood test for breast cancer detection” the grant will support a) the collection of blood samples from informed and consented female donors, b) multiplexed assay development using a suspended array technology and c) development of a prototype breast disease classification model. While there are other efforts around the world to develop biomarker based tests for breast disease detection and classification the “ITSIBIO blood test is unique in its approach, because, it could allow accurate classification of breast disease and employ a reliable and sensitive blood RNA detection method that does not require RNA isolation and polymerase chain reaction” added Dr Somiari.

April, 2008 Life Sciences-Ltda of Sao Paulo, Brazil appointed exclusive distributor

Posted by & filed under News.

ITSIBIO has signed a representation and distribution agreement with Life Sciences-Ltda (http://www.life-sciences.com.br), Sao Paulo, Brazil. This agreement, which is effective from March 14th 2008, gives Life Sciences exclusive rights to promote, market and distribute ITSIBIO products in Brazil. Clients in this territory can now place orders for all products through Life Sciences.

March, 2008 ITSIBIO signs distribution agreement with Precision Technologies PTE Ltd, Singapore

Posted by & filed under News.

ITSIBIO has signed a representation and distribution agreement with Precision Technologies PTE Ltd, Singapore (www.pretech.com.sg). This agreement, which is effective March 17th 2008, gives Precision Technologies exclusive rights to promote, market and distribute ITSIBIO products in Singapore, Malaysia and Indonesia. Clients in this territory can now place orders for all ITSIBIO products through Precision Technologies. Orders can be place by Phone: +6273-4573, Fax 6273-8898 or E-mail: scitech@pretech.com.sg.

January, 2008 NCI extends Blanket Purchase Agreement with ITSIBIO to 2010.

Posted by & filed under News.

NCI has extended the Blanket Purchase Agreement (BPA), originally signed with ITSIBIO in 2005, until 2010. This highly successful BPA which is managed by SAIC-Frederick, allows all NCI researchers to purchase genomics, proteomics and mass spectrometry services, and consumables from ITSIBIO at a pre-negotiated price. The BPA streamlines the process of outsourcing analytical support and locks-in lower prices for all investigators by leveraging economy of scale. Because the BPA contains legally binding confidentiality and non-disclosure clauses, researchers can fully discuss their experiments with the confidence that their ideas and scientific results will be safe and protected to the full extent required by law.

ITSIBIO receives Human Subject Research and ICH-GCP Certification.

ITSIBIO has received the Human Subject Research and International Conference on Harmonization (ICH) Good Clinical Practice (GCP) certifications. ICH-GCP brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry to ensure protection of human subjects and allow a more economical use of human, animal and material resources, and the elimination of unnecessary delay in the global development and availability of new medicines whilst maintaining safeguards on quality, safety and efficacy, and regulatory obligations to protect public health. ICH-GCP facilitates the dissemination and communication of information on harmonized guidelines, and the use such information/guidelines to encourage the implementation and integration of common standards. This significant milestone means that ITSIBIO’s staffs have a working knowledge of the principles and ethics associated with good clinical practices, understands Good Clinical Practices dictated by FDA (http://www.fda.gov/oc/gcp/regulations.html) and the ICH Requirements for Sponsors, Monitors, and Investigators. ITSIBIO affirms that all projects performed at ITSIBIO will strictly adhere to Use of Human Subject Research and ICH-GCP guidelines to allow the submission of the data for regulatory approval. Both certifications were received through the Collaborative Institution Training Initiative (CITI, http://www.citiprogram.org/).

ITSIBIO signs agreement with BioConsult, Jerusalem, Israel.

ITSIBIO has appointed BioConsult, Jerusalem, Israel (http://www.bioconsult.co.il/ ) as the exclusive distributor and representative in Israel. The agreement signed December 2007, gives BioConsult exclusive rights to promote, market and distribute all ITSIBIO products and services in Israel. Clients in Israel can now place orders through BioConsult via phone or by visiting their website.

ITSIBIO signs collaboration agreement with University of the Western Cape, Bellville, South Africa.

ITSIBIO has signed a collaboration agreement with the University of Western Cape Proteomics Research Group. Under the agreement, signed December 2007, both parties will collaborate in the areas of proteomics and sample preparation reagent development.

ITSI-Biosciences signs collaboration and distribution agreement with Innovative Biotech Ltd, Keffi Nigeria.

ITSIBIO enters the Nigerian market by signing a collaboration agreement with Innovative Biotech Limited (IBL), Keffi, Nigeria (www.innovativebiotechng.com). Under the agreement signed November 2007, ITSIBIO and IBL will collaborate to develop diagnostic assays for infectious diseases of national interest to Nigeria and the West African region. A distribution agreement signed in December 2007 during the visit of Simon Agwale, PhD, IBL CEO, to ITSIBIO head office in Johnstown, PA also gives IBL the exclusive rights to market, distribute and support ITSIBIO, Panomics Inc. and GenVault Inc products and services in Nigeria. All orders in the Nigerian market should now be placed through IBL Nigeria.

Bin Ali Medical Supplies appointed distributor for the Middle East market.

ITSIBIO announced today the appointment of Bin Ali Medical Supplies (BAMS), Abu Dhabi, United Arab Emirates (http://www.binalimed.com/) as the exclusive distributor and representative in the Middle East. The agreement signed in October 2007, allows BAMS to promote, market and distribute all ITSIBIO’s products and services in the Middle East. Clients in Middle East can now place orders through BAMS.

May, 2007

Posted by & filed under News.

ITSIBIO enters the Indian market by signing an exclusive agreement with SR Biosytem of New Delhi. Under the agreement signed May 2007, SR Biosytem will promote, market and distribute all ITSIBIO’s line of products, accessories and services in India. All orders in the Indian sub-continent should now be placed through SR Biosystem.

April, 2007

Posted by & filed under News.

ITSI signs an exclusive agreement with Separation Scientific (SA) (PTY) Ltd, of South Africa. Under the agreement that is effective from April 2007, Separation Scientific will promote, market and distribute all ITSIBIO’s products and services in the South Africa and other neighboring countries. Clients in Southern Africa should now place orders through Separation Scientific (SA) (PTY).

December 5 , 2006

Posted by & filed under News.

Pennsylvania Governor Rendell announces the investment of $500,000 to enable ITSI to expand its research facility and operations.

September 28, 2006

Posted by & filed under News.

ITSI representative invited to speak at the South African Bio2Biz International Biotechnology Conference, Durban, South Africa. A paper titled From Genomics and Proteomics to Bio-Business presented.

September 12, 2006

Posted by & filed under News.

ITSI representative invited to speak at the International Symposium on Inflammation: An Underlying Factor in Several Diseases, Ibadan, Nigeria. A paper titled Role of Proteomics in Inflammation Research presented as a keynote lecture.

September 7, 2006

Posted by & filed under News.

ITSI signs a collaboration agreement with the Advancement Center, College of Medicine, University of Nigeria. Under this agreement ITSI will work with the College of Medicine to develop integrated biomedical research programs and a biorepository to support cancer and complex disease research.

August 15, 2006

Posted by & filed under News.

ITSI signs an exclusive Representative and Distributorship agreement with InterSciences Inc., Markham Ontario, Canada. Under this agreement, InterSciences will promote, market and distribute the ITSIPREP™ line of products and easy-to-use kits for protein isolation, protein fractionation, protein precipitation, albumin removal and protein assay in Canada.

June 2006

Posted by & filed under News.

Dr Munir O. Azeez (Col.) of the Nigerian Army Medical Corps (NAMC) joins ITSI for six months advanced biomedical research training, as part of the training and collaboration agreement between ITSI and NAMC. Dr Azeez is interested in applying advanced proteomic technologies to study tissue from patients diagnosed with temporo-mandibular joint disease.

May 2006

Posted by & filed under News.

ITSI signs an exclusive distribution agreement with Funakoshi Japan. Funakoshi will promote, market and sell the ITSIPREP™ line of products in Japan.

www.funakoshi.co.jp

April 2006

Posted by & filed under News.

ITSI signs a non-exclusive Sales Representative Agreement with Grace Scientific LLC, Clarksburg, MD, USA. Grace Scientific will promote, market and sell ITSI’s services, especially 2D-DIGE and 2D-Image analysis services and all the ITSIPREP™ line of products in the Maryland, Washington DC and Virginia area.

March 2006

Posted by & filed under News.

ITSI signs an exclusive Representative and Distributorship agreement with Rainbow Biotechnology Co., Taipei, Taiwan. Rainbow will promote, market and distribute the ITSIPREP™ line of products including optimized and easy-to-use kits for protein isolation, protein fractionation, protein precipitation, albumin removal and protein assay.

www.rainbowbiotech.com.tw

February 1 2006

Posted by & filed under News.

Itsi-Biosciences has moved to a new, larger location. Images of our new facility and additional information will available online shortly. Please see the Contact page for our new address.

January 2006

Posted by & filed under News.

ITSI appoints Syngenic Biotecnologia Ltda., Sao Paolo Brazil as the exclusive distributor of the ITSIPREP™ line of products in Brazil. The agreement, which was signed in October 2005, covers all the optimized and easy-to-use kits for protein isolation, protein fractionation, protein precipitation, albumin removal and protein assay.

November 24 2005

Posted by & filed under News.

ITSI-Biosciences President and CSO Richard Somiari Ph.D. is prominently featured in the 11/24/05 issue of Nature.

September 14 2005

Posted by & filed under News.

Itsibio represented at GE Healthcare 2D-DIGE Users Group meeting in Nashville, TN. Presents paper “Application of 2D-DIGE technology for the analysis of clinical specimens.”

September 9 2005

Posted by & filed under News.

Robin L. Fisher, Director Asia & Europe, International Business Development, PA DCED, Mr. Donald M. Bonk, International Trade Manager, SAPDC and Ms. Sushama A Kanetkar, Director, PA Trade Representative Office in India, and Supriya, Trade & Investment Advisor, PA Trade Office India visit Itsibio corporate headquarters/laboratory to discuss export opportunities and entry into the Indian market.

September 8 2005

Posted by & filed under News.

ITSIBIO invited to exhibit products at the Cambria County Chamber of Commerce Small Business Expo in Ebensburg, PA

August 12 2005

Posted by & filed under News.

Itsibio, Applied Isotope Technologies and MountainTop Technologies sign agreement to explore business opportunities of mutual interest involving proteomics.

August 5 2005

Posted by & filed under News.

Itsibio signs a distribution agreement with Biomedical Marketing Associates. BMA will market and distribute ITSI’s proteomics products including protein isolation, fractionation and assay kits in 5 states: Michigan, Ohio, Kentucky, West Virginia and Western Pennsylvania.

July 22 2005

Posted by & filed under News.

David H. Fyock, Chairman/CEO, MountainTop Technologies Inc., Matt Pamuku, President, Applied Isotope Technologies, Inc., Prof. HM (Skip) Kingston, PhD, Duquesne University and Dr. Steve Ayanruoh, MD, Chairman, Ruskat Medical Equipment Corp and Applied Medical Technologies, visit Itsibio to discuss collaboration and teaming agreement.

July 15 2005

Posted by & filed under News.

Stephen C. Metzger, Director Business Lending Services of Southern Allegheny Planning & Development Commission, Altoona, PA visits itsibio to discuss funding opportunities and support. SAPDC is supporting itsibio’s effort to export bioanalytical reagents produced in Johnstown, PA to Mexico and Brazil, and to access funds through the Small Business First loan program.

July 11 2005

Posted by & filed under News.

Prof. Francis A.A. Adeniyi, Dean, Faculty of Basic Medical Sciences and Ag. Director, Institute for Advanced Medical Research & Training (IMRAT), University of Ibadan, Ibadan, Nigeria visits itsi-Biosciences to discuss collaboration in the areas of biomedical research, bioanalytical support, tissue banking and data center development.

July 8 2005

Posted by & filed under News.

Itsibio acquires ProteinChip System Series 4000 Enterprise Edition Surface Enhanced Laser Desorbed Ionization – Time of Flight (SELDI-Tof) fromCiphergen Biosystems as part of an emerging collaboration between Itsibio and Ciphergen. The system, which is the best for analysis of serum, plasma, urine and saliva will support internal biomarker discovery programs and will enable Itsibio to provide contract biomarker discovery services to academia and pharmaceutical industries.

July 7 2005

Posted by & filed under News.

Itsibio representatives visit NCI-Frederick, Frederick MD. Present seminar “Integrating emerging high throughput technologies for complex disease research”

April 19 2005

Posted by & filed under Programs & Events.

Mr. Joseph Burke, Director, Americas, So. Africa, Mid. East & Oceania Grp., PA DCED, Mr. Donald M. Bonk, International Trade Manager, SAPDC and Ms. Silvia Alonso, Senior Trade Specialist for PA in Mexico visit itsibio corporate headquarters/laboratory.

April 13 2005

Posted by & filed under Programs & Events.

Itsibio attends American Society of Breast Disease (ASBD) annual meeting (April 13-16 2005) in Las Vegas, NV. Itsibio representative serves on the Outreach and special populations committee and is a member of the Expert working group on risk assessment of the ASBD.

March 22 2005

Posted by & filed under Programs & Events.

Itsibio representative visits University of Nigeria, Nsukka, Nigeria and presents seminar “Emerging high throughput technologies and complex disease research” Meets with Director, University Resource Foundation, Provost, University of Nigeria Teaching Hospital, Chief Medical Director, University of Nigeria Teaching Hospital and other senior faculty and university administrators to discuss partnership between both organizations.

March 19 2005

Posted by & filed under Programs & Events.

Itsibio representative visits the Institute of Advanced Medical Research & Training, University of Ibadan, Nigeria and University College Hospital, Ibadan, Nigeria. Presents a seminar &;Advances in High throughput Biomedical Research & Personalized Medicine. Meets with Prof E. Bababunmi, Prof. Francis AA Adeniyi and Prof. Idowu Yinka and other senior faculty members to discuss partnership between both organizations.

March 18 2005

Posted by & filed under Programs & Events.

Itsibio representative attends the launching of the Nigerian Army Medical Corps/School (NAMC/S) rollback malaria program. Meets with the Honorable Minister of State for defense Dr. Roland Oritsejafor, Lt. Gen ML Agwai (Chief of Army Staff) and Maj. Gen B. E. Abang (Commandant NAMC/S).

March 4 2005

Posted by & filed under Programs & Events.

Itsibio representative visits and presents a seminar; Application of emerging high throughput technologies in complex disease research; at the College of Pharmacy, University of Houston, TX. Meets with Dean Sunny Ohia and senior faculty.

January 3 2005

Posted by & filed under Programs & Events.

Itsibio formally opens ultra-modern laboratory for genomics and proteomics research and provision of bioanalytical services.